A5017552956- Renal Transplantation Outcomes and Treatments
- Organ Donation and Transplantation
- Organ Transplantation Techniques and Outcomes
- Neurological Complications and Syndromes
- Cytomegalovirus and herpesvirus research
- Renal and Vascular Pathologies
- Organ and Tissue Transplantation Research
- Renal Diseases and Glomerulopathies
- Dialysis and Renal Disease Management
- Pregnancy and Medication Impact
- Transplantation: Methods and Outcomes
- Polyomavirus and related diseases
- Pneumocystis jirovecii pneumonia detection and treatment
- COVID-19 Clinical Research Studies
- HIV/AIDS drug development and treatment
- Pharmacological Effects and Toxicity Studies
- Viral-associated cancers and disorders
- Liver Disease and Transplantation
- Complement system in diseases
- Hepatitis C virus research
- Palliative Care and End-of-Life Issues
- Grief, Bereavement, and Mental Health
- Global Maternal and Child Health
- Long-Term Effects of COVID-19
- Public Health in Brazil
Santa Casa de Misericórdia de Marília
2006-2025
Santa Casa Hospital
2011-2024
Universidade de São Paulo
2015-2024
Irmandade da Santa Casa de Misericórdia de São Paulo
1992-2023
Universidade Federal de Ciências da Saúde de Porto Alegre
2009-2023
Hospital de Clínicas de Porto Alegre
2020-2022
Instituto Federal de Educação, Ciência e Tecnologia de Minas Gerais
2020
Universidade Federal de São Paulo
2019
Hospital São Vicente
2010-2018
Hospital Israelita Albert Einstein
2016
Recipients of extended criteria donor (ECD) kidneys are at increased risk for graft dysfunction/loss, and may benefit from immunosuppression that avoids calcineurin inhibitor (CNI) nephrotoxicity. Belatacept, a selective costimulation blocker, preserve renal function improve long-term outcomes versus CNIs. BENEFIT-EXT (Belatacept Evaluation Nephroprotection Efficacy as First-line Immunosuppression Trial-EXTended donors) is 3-year, Phase III study assessed more (MI) or less intensive (LI)...
The clinical profile of belatacept in kidney transplant recipients was evaluated to determine if earlier results the BENEFIT study were sustained at 3 years. is a randomized year, phase III adults receiving from living or standard criteria deceased donor. Patients more (MI) less intensive (LI) regimen belatacept, cyclosporine. 471/666 patients completed ≥3 years therapy. A total 92% (MI), (LI), and 89% (cyclosporine) survived with functioning graft. mean calculated GFR (cGFR) ∼21 mL/min/1.73...
Recipients of extended-criteria donor (ECD) kidneys have poorer long-term outcomes compared to standard-criteria kidney recipients. We report 3-year from a randomized, phase III study in recipients de novo ECD (n = 543) assigned (1:1:1) either more intensive (MI) or less (LI) belatacept regimen, cyclosporine. Three hundred twenty-three patients completed treatment by year 3. Patient survival with functioning graft was comparable between groups (80% MI, 82% LI, 80% cyclosporine). Mean...
<h2>Abstract</h2> Two prospective, randomized studies evaluated everolimus 1.5 vs. 3 mg/day with steroids and low-exposure cyclosporine (CsA) (C<sub>2</sub> monitoring) in <i>de novo</i> renal transplant patients. Everolimus dosing was adjusted to maintain a minimum trough level of ng/mL. Study 1 (A2306; n=237) had no induction therapy; 2 (A2307; n=256) basiliximab administered (Days 0 4). The primary endpoint function at 6 months. CsA C<sub>2</sub> target levels, initially 1200 ng/mL 600 2,...
Prolonged use of calcineurin inhibitors (CNIs) in kidney transplant recipients is associated with renal and nonrenal toxicity an increase cardiovascular risk factors. Belatacept-based regimens may provide a treatment option for patients who switch from CNI-based maintenance immunosuppression.
familiar, da manutenção clínica do doador falecido e de contraindicações mal atribuídas.
The safety profiles of standard therapy versus everolimus with reduced-exposure calcineurin inhibitor (CNI) using contemporary protocols in de novo kidney transplant recipients have not been compared detail.TRANSFORM was a randomized, international trial which patients were randomized to CNI (N = 1014) or mycophenolic acid (MPA) standard-exposure 1012), both induction and corticosteroids.Within the population (everolimus 1014, MPA adverse events suspected relation study drug occurred 62.9%...
Background Kidney transplant (KT) recipients are considered a high-risk group for unfavorable outcomes in the course of coronavirus disease 2019 (COVID-19). Aim To describe clinical aspects and COVID-19 among KT recipients. Methods This multicenter cohort study enrolled 1,680 diagnosed with between March November 2020, from 35 Brazilian centers. The main outcome was 90-day cumulative incidence death, entire according to acute kidney injury (AKI) renal replacement therapy (RRT) requirement....
Background1-year data from this trial showed the noninferiority of a novel once-daily extended-release tacrolimus (LCPT; Envarsus XR) to immediate-release (IR-Tac) twice daily after kidney transplantation.Study DesignFinal 24-month analysis 2-armed, parallel-group, randomized, double-blind, double-dummy, multicenter, phase 3 trial.Setting & Participants543 de novo recipients randomly assigned LCPT (n = 268) or IR-Tac 275); 507 (93.4%) completed study.InterventionLCPT tablets once at 0.17...
O Sistema Nacional de Transplantes (SNT) Brasileiro coordena e regulamenta o, provavelmente, maior programa transplantes públicos do mundo. Desde o seu estabelecimento, em 1997, número renais aumentou 920 (5,8 pmp), 1988, para 4.630 (24,1 2010. Esse crescimento foi primariamente devido ao aumento no doadores efetivos (de 1,8 pmp 1998 9,3 2010), com correspondente rins transplantados falecidos (3,8 1999 versus 9,9 2010). órgãos vivos não significativamente, 1.065 (6,7 1998, 1.641 (8,6 2010,...
Planned conversion from tacrolimus to sirolimus was evaluated in de novo kidney transplant recipients. In this multicenter, randomized, open-label study, 297 patients were initially treated with tacrolimus, mycophenolate sodium and prednisone. Of the 283 reaching 3 months, 97 converted (SRL), 107 maintained on (TAC) 79 receiving TAC without criteria undergo intervention at month (TACex). The primary objective show superior estimated glomerular filtration rate (eGFR) SRL group 24. 258 who...
Small children are a challenging group in whom to perform KT. This retrospective study analyzed the results of 62 KTs weighing <15 kg, performed between 1998 and 2010, using extraperitoneal access anastomosis renal vessels donors aorta IVC or iliac recipients. Thirty-two (51.6%) grafts were LRDTs 30 (48.4%) DDRTs-28 them pediatric. The mean age at KT was 3.7 ± 2.2 yr (1-12), weight 12.3 2.1 kg (5.6-14.9). Ten weighed <10 five (8.1%) presented previous thrombosis venous system. At one yr,...
We reviewed the current status of liver transplantation in Latin America. used data from American and Caribbean Transplant Society national organizations societies, as well information obtained local transplant leaders. America has a population 589 million (8.5% world population) more than 2,500 transplantations are performed yearly (17% activity), resulting 4.4 transplants per people (pmp) year. The number grows at 6% year region, particularly Brazil. top rates were found Argentina (10.4...
Tuberculosis (TB) is a great challenge in kidney transplantation, and often associated with high morbidity mortality. The aim of this study was to evaluate the epidemiology, clinical manifestations, impact TB transplant (KT) recipients.We performed retrospective analysis cohort adult KT recipients from 2000 2012, follow-up until July 2014.Among 1737 evaluated, 60 developed TB: 5% cumulative incidence, an incidence rate 589.4 cases/100,000 patient-years. Median time diagnosis 13.4 months, 40%...
This analysis, using data from the Brazilian kidney transplant (KT) COVID-19 study, seeks to develop a prediction score assist in risk stratification KT recipients. In this 1379 patients (35 sites) were enrolled, and machine learning approach was used fit models derivation cohort. A reduced Elastic Net model selected, accuracy predict 28-day fatality after diagnosis, assessed by area under ROC curve (AUC-ROC), confirmed validation The better calibration values build applicable ImAgeS score....
Post-transplant lymphoproliferative disease (PTLD) is an uncommon but life-threatening complication of solid-organ and blood stem-cell transplants. It responds poorly to therapy, including reduction immunosuppression, interferon, antivirals or chemotherapy. Small series PTLD successfully treated with rituximab have been reported, experimental studies suggest that rapamycin inhibits growth human Epstein-Barr virus-transformed B lymphocytes. We report two cases after renal transplantation were...